中国药物警戒 ›› 2024, Vol. 21 ›› Issue (9): 1071-1074.
DOI: 10.19803/j.1672-8629.20240167

• 安全与合理用药 • 上一篇    下一篇

达格列净片致严重便秘1例分析

卢靖1,2, 喻珊珊1, 童菲1, 林卓慧2, 宋路瑶1,*   

  1. 1南方医科大学珠江医院药学部, 广东 广州 510280;
    2广州市荔湾中心医院药剂科, 广东 广州 510170
  • 收稿日期:2024-03-12 出版日期:2024-09-15 发布日期:2024-09-14
  • 通讯作者: *宋路瑶,女,博士,主管药师,临床药学。E-mail:songluyao.nice@163.com
  • 作者简介:卢靖,男,硕士,主管药师,临床药学。
  • 基金资助:
    广东省医院协会医院药学科研专项基金（YSGL-202202）; 广州市科技计划项目（202102020539）

One case of severe constipation caused by dapagliflozin

LU Jing1,2, YU Shanshan1, TONG Fei1, LIN Zhuohui2, SONG Luyao1,*   

  1. 1Department of Pharmacy, Zhujiang Hospital of Southern Medical University, Guangzhou Guangdong 510280, China;
    2Department of Pharmacy, Liwan Central Hospital of Guangzhou, Guangzhou Guangdong 510170, China
  • Received:2024-03-12 Online:2024-09-15 Published:2024-09-14

PDF (PC)

45

摘要： 目的 提高医务人员对达格列净片致严重便秘的警惕性,为达格列净的安全使用提供参考。方法 分析1例由达格列净片导致严重便秘患者的诊疗经过,对相关文献进行归纳与总结,探讨钠-葡萄糖共转运体2抑制剂（SGLT-2i）导致严重便秘的发生情况、可能机制和防治措施。结果 患者在使用达格列净片后出现严重便秘,停药后患者便秘症状好转,再次使用达格列净片后患者又出现便秘,立即停药并予润肠通便治疗后,便秘症状好转。其不良反应因果关系评估为“肯定”,故判断该患者严重便秘由达格列净片所致。结论 便秘不仅严重影响患者生活质量,还可能诱发心血管事件,应加强对达格列净片及SGLT-2i类药物致便秘不良反应的重视及用药教育。

关键词: 达格列净, 便秘, 钠-葡萄糖共转运体2抑制剂, 胃肠系统疾病, 药品不良反应

Abstract: Objective To remind health care professionals to be more alert to the risk of severe constipation associated with dapagliflozin and to provide reference for safe use of this drug. Methods The clinical process of treating a patient who developed severe constipation after taking dapagliflozin tablets was analyzed. Based on related literature, the possible mechanisms and treatment regimens of severe constipation caused by sodium-glucose cotransporter 2 inhibitors (SGLT-2i) were studied. Results One patient developed severe constipation after taking dapagliflozin. After discontinuation of the drug, the patient's constipation improved. However, upon re-administration of dapagliflozin, the patient relapsed into constipation. Immediately after drug withdrawal and treatment with laxatives to moisten the intestines, the patient's conditions improved. The causal relationship of adverse reactions was defined as “definite”, so the severe constipation of this patient was considered to have been caused by dapagliflozin. Conclusion Constipation poses a significant threat to patients' quality of life and may potentially precipitate cardiovascular events. Therefore, it is imperative to enhance clinicians' awareness and pharmacological surveillance regarding the adverse effects of constipation associated with dapagliflozin and SGLT-2i.

Key words: dapagliflozin, constipation, sodium-glucose cotransporter-2 inhibitors (SGLT- 2i), gastrointestinal disorders, drug adverse reaction

中图分类号: